On specialty pharmaceuticals: reflections of a second-year medical student.
作者信息
Breitbart Ross E
机构信息
Medical Student Researcher, Department of Health Policy Jefferson Medical College, Philadelphia.
出版信息
Biotechnol Healthc. 2006 Oct;3(5):41-4.
Abstract
High cost and lack of evidence-based data for biologics used to treat rare diseases raise coverage questions for payers. Are clinical practice guidelines the answer?
摘要
相似文献
1
On specialty pharmaceuticals: reflections of a second-year medical student.
Biotechnol Healthc. 2006 Oct;3(5):41-4.
2
Managing the cost of specialty pharmaceuticals.
Nurs Econ. 2004 Sep-Oct;22(5):245-50, 227.
3
EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.
Int J Technol Assess Health Care. 2017 Jan;33(4):534-540. doi: 10.1017/S0266462317000903. Epub 2017 Oct 25.
4
PBM Consolidation: Better Pricing or Just Less Competition?: The growth of specialty pharmaceuticals, including biologics, is forcing payers and employers to look at cost-saving strategies for managing those drugs. How will they do it if only one large PBM rules the specialty pharmacy network?
Biotechnol Healthc. 2012 Spring;9(1):10-4.
5
The Effect of Medical Student Volunteering in a Student-Run Clinic on Specialty Choice for Residency.
Cureus. 2017 Jan 9;9(1):e967. doi: 10.7759/cureus.967.
6
Mapping US commercial payers' coverage policies for medical interventions.
Am J Manag Care. 2016 Sep 1;22(9):e323-8.
7
Part 1: Distribution models for biologics and other specialty pharmaceutical products: In this first of a two-part series, we examine the distribution landscape for specialty pharmaceuticals. A manufacturer's strategy for the flow of product to patient has important implications for payers and for the success of a new biologic therapy.
Biotechnol Healthc. 2012 Summer;9(2):8-13.
8
Breaking the Bank: Three Financing Models for Addressing the Drug Innovation Cost Crisis.
Am Health Drug Benefits. 2015 May;8(3):118-26.
9
Setting the Bar Higher For Off-Label Use of Biologics: Off-label use of biologics is common as physicians strive for optimal treatment. Patients want whatever works. Drug makers want expanded labeling, but payers chafe at the lack of efficacy data. Is there an answer to this conundrum?
Biotechnol Healthc. 2011 Fall;8(3):14-8.
10
The impact of specialty pharmaceuticals as drivers of health care costs.
Health Aff (Millwood). 2014 Oct;33(10):1714-20. doi: 10.1377/hlthaff.2014.0558.
本文引用的文献
1
Making the case to managed care: the science of marketing biologics.
Biotechnol Healthc. 2004 Dec;1(6):16-25.
2
Valued lives: Britain stirs outcry by weighing benefits of drugs versus price; government arm finds pills for Alzheimer's too costly, angering patients, Pfizer.
Wall St J (East Ed). 2005 Nov 22:A1, A11.
3
4
Lucrative niches: how drugs for rare diseases became lifeline for companies.
Wall St J (East Ed). 2005 Nov 15:A1, A18.
5
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Health Technol Assess. 2006 Jan;10(1):iii-iv, ix-xi, 1-160. doi: 10.3310/hta10010.
6
A conversation with Jayson Slotnik, MPH, JD. Trying to make biotech attractive to payers.
Manag Care. 2005 Nov;14(11):62-4, 71.
7
Variability and growth in spending for outpatient specialty pharmaceuticals.
Health Aff (Millwood). 2005 Jul-Aug;24(4):1117-27. doi: 10.1377/hlthaff.24.4.1117.
8
Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.
J Pediatr. 2004 Jan;144(1):112-20. doi: 10.1016/j.jpeds.2003.10.067.
9
American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children--2003 update.
Endocr Pract. 2003 Jan-Feb;9(1):64-76. doi: 10.4158/EP.9.1.64.
10
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
Am J Med. 2002 Aug 1;113(2):112-9. doi: 10.1016/s0002-9343(02)01150-6.
Zotero 插件